To develop new therapies targeting host-gut microbial drug metabolism and other new health interventions, and to prevent the gastrointestinal effects of levodopa use in the first place, we found that the conversion efficiency of chorismate to L-tyrosine in the levodopa production pathway is a key factor limiting the further efficient production of levodopa. Therefore, by screening the key rate-limiting enzyme gene tyrA from different sources and optimizing the RBS of the obtained excellent genes, we modified the rate-limiting enzyme at two levels in order to obtain effective synthetic elements. This is necessary to further enhance the industrial application of levodopa biosynthesis. The detailed component composition is shown in the table below (Table 1).

Table1.The parts Collection